CSPC Innovation's SYS6041 ADC gets FDA trial nod

CSPC Innovation Pharmaceutical (SZSE:300765) announced that its holding subsidiary, CSPC Jishi Pharmaceutical, has received FDA approval to initiate clinical trials in the United States for SYS6041, an antibody-drug conjugate (ADC). The investigational new drug (IND) application, numbered 175990, has passed the FDA's safety review, allowing Jishi to conduct clinical research on advanced solid tumors. SYS6041 is a monoclonal antibody-drug conjugate designed to bind to specific receptors on tumor surfaces, enter cells through endocytosis, and release toxins to kill cancer cells. Preclinical studies have shown that SYS6041 has good anti-tumor effects on a variety of cancers, and has high clinical development value. This product has submitted multiple patent applications in China and abroad.